The study is being carried out by the platform VISION (Vaccine Immunology Studies – Indian Outbreak-response Network) which includes top public and private research institutes.
The investment will support the company’s plans to expand its network of specialised surgical hospitals across India.
The investment case for health technology in India is frequently overstated in one direction and understated in another
The financing includes a four-year interest-only period, extendable to five years if a net sales milestone is achieved
The company has achieved a turnover of around Rs 100 crore in FY 2025–26 and aims to achieve a turnover of Rs 500 crore in next three years
The funding will be spread over four years, with BXLS also eligible for regulatory and commercial milestones, plus royalties on worldwide sales
The capital was raised via multiple-tenure non-convertible debentures (NCDs) and commercial papers
ALV-100 is a bifunctional fusion protein combining glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonism with glucagon-like peptide-1 receptor agonism
Collaboration funds participating biotechs to access Lilly predictive models through the Revvity Signals Xynthetica offering
Subscribe To Our Newsletter & Stay Updated
